Analytical Tool: Competitive Outlook on HCVBioSeeker Group ABJune 22, 2004 175 Pages - SKU: BIOS1021676 |
This Analytical Tool is especially designed to deal with the fierce and changing competitive business environment for the pharmaceutical market of chronic HCV infection. Since Hoffmann-La Roche's entry into this $3 billion market, previously dominated by Schering-Plough, the competitive as well as the business development situation has changed significantly. The healthy competition which now is in place will be beneficiary to both the industry itself and those in need for better HCV drugs. Market dominance by one big pharma provides far fewer business opportunities compared to two companies fighting to be the world leader. BioSeeker has conducted fresh research on both the current world status of R&D and business development in HCV. The research and analysis is built on more than 150 companies from over 18 different countries and include more than 160 pipeline drugs in development for HCV. All of this information is included into a searchable CD-ROM database, so you may search and find any company profile or pipeline drug of interest for further personal research. The competitive analysis gives you an up to date of the HCV competitive landscape, involving 66 selected collaborations divided into 7 major clusters of companies, whereof six are interconnected and one cluster stands alone. Find out key data on each cluster, such as Type of Collaboration (9 classes), R&D Focus, Number of Drugs in Development, Competitive Edge etc. BioSeeker's competitive analysis sheds light and increases understanding of alliances that future partners are involved in, so that you can minimize the risk that competitors can gain information about what you are planning to do. All of this collaborative information, as well as several additional smaller collaborations, is also found in the CD-ROM database. BioSeeker has designed special tracking number, quoted in the report, which can be used to look up any collaborative activity in the database for further information. BioSeeker's HCV R&D analysis thoroughly discusses drug and vaccine development world wide. The analysis covers more than 108 pipeline drugs, ranging from pre-clinical to phase III. Key points in the analysis are to deduce trends in HCV drug development, evaluate all major drug targets and outline country by country efforts in HCV. The analysis also addresses the issue of what demands are raised on new HCV drugs and how the industry gradually will move over from interferon to small molecular drugs and combination therapies thereof. Special emphasis is put on linking analysis with concrete R&D projects through high value tables, in order to facilitate further research. This Analytical Tool geared towards people in business development, competitive intelligence, and for R&D project responsibles in HCV. |
Related Markets
Hepatitis Reports
- Chinese Markets for Hepatitis Drugs
- Liver Disease Treatments: The Global Market
- Hepatitis Market to 2017 - Strong Hepatitis-C Pipeline, Large Number of Strategic Consolidations and Cost Effective Treatments will Drive the Market
- Hepatitis B Vaccines - Pipeline Assessment and Market Forecasts to 2018
- Hepatitis C Global Clinical Trials Review, H2, 2011